iShares Intermediate-Term Corporate Bond ETF IGIB 深 沪
已收盘 04-02 16:00:00 美东时间
53.19
+0.150
+0.28%
华盛通- 最 高53.27
- 今 开52.96
- 成交量 260.68万股
- 最 低 52.945
- 昨 收 53.04
- 总市值 175.71亿
- 52周最高 54.1462
- 市盈率 静 --
- 换手率 0.79%
- 52周最低 48.7542
- 委 比 -97.73%
- 总股本 3.30亿
- 历史最高 54.1462
- 量 比 0.72
- 振 幅 0.61%
- 历史最低 37.5638
- 每 手 1
- 风险率 1.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Infinimmune Enters Collaboration With Merck To Discover Novel Human Antibody Therapeutics
BRIEF-Infinimmune Enters Collaboration With Merck To Discover Novel Human Antibody Therapeutics Merck & Co Inc MRK.N : INFINIMMUNE ENTERS COLLABORATION WITH MERCK TO DISCOVER NOVEL HUMAN ANTIBODY THERAPEUTICS INFINIMMUNE: ELIGIBLE TO RECEIVE MILESTONE PAYMENTS FROM MERCK ASSOCIATED WITH PROGRESS OF
03-31 20:47
BRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients
BRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients March 31 (Reuters) - Novo Nordisk A/S NOVOb.CO : NOVO NORDISK: ANNOUNCED NEW MULTI-MONTH SUBSCRIPTION PROGRAM FOR WEGOVY FOR ELIGIBLE SELF-PAY PATIENTS NOVO NORDISK: WEGOVY SUBSCRIPTION PROGRA
03-31 19:32
BRIEF-Nasdaq To Update Nasdaq-100 Index Methodology
BRIEF-Nasdaq To Update Nasdaq-100 Index Methodology March 30 (Reuters) - Nasdaq Inc NDAQ.O : NASDAQ: PROPOSAL FOR “FAST ENTRY” FOR NEW NASDAQ LISTED LARGE COMPANIES WILL BE ADOPTED WITH SOME MODIFICATIONS NASDAQ: PROPOSAL FOR CALCULATION OF MARKET CAP FOR ELIGIBILITY PURPOSES WILL BE ADOPTED AS PROP
03-30 20:00
BRIEF-Insilico Medicine & Tenacia Biotechnology Expand AI-Driven CNS Collaboration
BRIEF-Insilico Medicine & Tenacia Biotechnology Expand AI-Driven CNS Collaboration March 26 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK : INSILICO MEDICINE AND TENACIA BIOTECHNOLOGY EXPAND AI-DRIVEN CNS COLLABORATION WITH DEAL VALUE UP TO US$94.75 MILLION INSILICO MEDICINE CAYMAN TOPCO - CO A
03-26 22:37
BRIEF-Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851
BRIEF-Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851 March 23 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O : LEXICON PHARMACEUTICALS AND NOVO NORDISK ANNOUNCE INITIATION OF PHASE 1 STUDY WITH ORAL OBESITY DRUG CANDIDATE LX9851
03-23 20:09
Shape the Future of TradingKey: Rate & Win a Share of $200 Prize Pool!
Your Feedback is Our Ultimate Strategy 🚀 In the fast-paced U.S. stocks market, everyone needs a powerful ally. TradingKey is built to help every investor
03-16 04:41
BRIEF-GSK & Alfasigma Announce Agreement On Global Rights For Linerixibat
BRIEF-GSK & Alfasigma Announce Agreement On Global Rights For Linerixibat March 9 (Reuters) - GSK plc GSK.L : GSK PLC - GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS GSK PLC - GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS GSK - ELIGIBLE FOR $20 MILLION ON EU/UK APPROVAL AND UP TO $270 MILL
03-09 15:22
BRIEF-Hungary's Richter acquires women’s health discovery portfolio of U.S.-based Celmatix
BRIEF-Hungary's Richter acquires women’s health discovery portfolio of U.S.-based Celmatix March 3 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says: ACQUIRES WOMEN’S HEALTH DISCOVERY PORTFOLIO OF US BASED CELMATIX CELMATIX WILL RECEIVE AN UPFRONT PAYMENT AND WILL BE ELIGIBLE TO RECEIVE D
03-03 15:03
BRIEF-New Vinfast Vf8 Now Eligible For $5,000 Federal Ev Rebate In Canada
BRIEF-New Vinfast Vf8 Now Eligible For $5,000 Federal Ev Rebate In Canada March 2 (Reuters) - VinFast Auto Ltd VFS.O : NEW VINFAST VF8 NOW ELIGIBLE FOR $5,000 FEDERAL EV REBATE IN CANADA Source text: ID:nBwbGSVFGa Further company coverage: VFS.O (( Reuters.Briefs@thomsonreuters.com ;))
03-02 22:21
BRIEF-Astellas & Vir Biotechnology Collaborate To Advance VIR-5500
BRIEF-Astellas & Vir Biotechnology Collaborate To Advance VIR-5500 Feb 23 (Reuters) - Astellas Pharma Inc 4503.T : ASTELLAS PHARMA: CO & VIR BIOTECHNOLOGY ENTERED GLOBAL STRATEGIC COLLABORATION TO ADVANCE VIR-5500 FOR TREATMENT OF PROSTATE CANCER ASTELLAS: CO WILL OBTAIN EXCLUSIVE RIGHTS TO COMMERCI
02-24 06:00
